Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer

Next Previous
Trial Profile

A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capivasertib (Primary) ; Danvatirsen (Primary) ; Datopotamab deruxtecan (Primary) ; Durvalumab (Primary) ; Oleclumab (Primary) ; Paclitaxel (Primary) ; Selumetinib (Primary) ; Trastuzumab-deruxtecan (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BEGONIA
  • Sponsors AstraZeneca; AstraZeneca AB

    • Most Recent Events

    • 09 Dec 2023 Trial design presented at the 46th Annual San Antonio Breast Cancer Symposium
    • 01 Dec 2023 According to Daiichi Sankyo Company Media Release, results from this study will be presented at the San Antonio Breast Cancer Symposium, 2023.
    • 14 Nov 2023 Planned number of patients changed from 275 to 320.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top